Freeline announces supply agreement for haemophilia B program
23 sept. 2020 07h00 HE
|
Freeline Therapeutics
LONDON, Sept. 23, 2020 (GLOBE NEWSWIRE) -- Freeline Therapeutics Holdings plc (Nasdaq: FRLN) (the “Company” or “Freeline”), a clinical stage, fully-integrated, next generation, systemic, AAV-based...
Freeline to participate in the Morgan Stanley Virtual 18th Annual Global Healthcare Conference
10 sept. 2020 07h00 HE
|
Freeline Therapeutics
LONDON, Sept. 10, 2020 (GLOBE NEWSWIRE) -- Freeline Therapeutics Holdings plc (Nasdaq: FRLN) (the “Company” or “Freeline”), a clinical-stage, fully integrated, next generation, systemic AAV-based...
Freeline Announces Pricing of Initial Public Offering
07 août 2020 02h49 HE
|
Freeline Therapeutics
LONDON, Aug. 07, 2020 (GLOBE NEWSWIRE) -- Freeline Therapeutics Holdings plc (“Freeline”), a clinical-stage, fully integrated, next generation, systemic AAV-based gene therapy company with the...
Freeline Launches Roadshow for Initial Public Offering
03 août 2020 06h30 HE
|
Freeline Therapeutics
LONDON, Aug. 03, 2020 (GLOBE NEWSWIRE) -- Freeline Therapeutics Holdings plc (“Freeline”), a clinical-stage, fully integrated, next generation, systemic AAV-based gene therapy company with the...
Freeline files registration statement for proposed initial public offering in the United States
20 juil. 2020 02h00 HE
|
Freeline Therapeutics
LONDON, July 20, 2020 (GLOBE NEWSWIRE) -- Freeline, a clinical-stage, fully integrated, next generation, systemic AAV-based gene therapy company with the ambition of transforming the lives of...
Freeline presents new Haemophilia B data at the International Society on Thrombosis and Haemostasis (ISTH) 2020 Meeting
13 juil. 2020 11h45 HE
|
Freeline Therapeutics
- Updated FLT180a data in the B-AMAZE study in severe Haemophilia B patients demonstrated the potential for sustained normal FIX activity levels - - Additional data were presented in 5 poster...
Freeline Announces Additional Financing Plans
30 juin 2020 02h00 HE
|
Freeline Logo
LONDON, June 30, 2020 (GLOBE NEWSWIRE) -- Freeline, a biotechnology company focused on developing curative gene therapies for chronic systemic diseases, today announced that it expects to consider...
Freeline Closes $120 Million Series C Financing Round
30 juin 2020 02h00 HE
|
Freeline Logo
LONDON, June 30, 2020 (GLOBE NEWSWIRE) -- Freeline, a biotechnology company focused on developing curative gene therapies for chronic systemic diseases, today announced the closing of a $120 million...
Freeline announces acceptance of Late Breaking Abstract at the International Society on Thrombosis and Haemostasis (ISTH) 2020 Meeting
29 juin 2020 09h00 HE
|
Freeline Logo
- Updated data will be presented in an oral presentation on the efficacy and safety of AAV gene therapy FL180a in the B-AMAZE study in severe haemophilia B patients - - Additional data will be...